Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the appointment of Adam Davenport as Chief Discovery Officer. A seasoned drug hunter and innovator, Adam brings over 25 years of hands-on experience in life sciences and partnership management. His expertise has significantly contributed to the advancement of drug candidates and clinical assets through strategic governance and leadership roles.

“We are thrilled to welcome Adam Davenport to Proxygen as chief discovery officer,” says Bernd Boidol, chief executive officer of Proxygen. “Adam’s exceptional track record in drug discovery and development, combined with his proven leadership in advancing innovative therapies, aligns perfectly with Proxygen’s mission to pioneer the next generation of targeted protein degraders. His deep expertise and passion for science will be instrumental in accelerating our pipeline and translating our groundbreaking research into transformative therapies for patients worldwide.”

Prior to joining Proxygen, Adam served as chief R&D officer at Dalriada Drug Discovery, where he led oncology-focused discovery collaborations and drove the development of internal capabilities. His illustrious career also includes more than two decades at Evotec, where he amassed extensive experience across the drug discovery spectrum, from Hit Identification to Investigational New Drug (IND) applications. His work spanned diverse modalities, target classes—including GPCRs, ion channels, and kinases—and therapeutic areas such as oncology, inflammation, pain, metabolic disorders, and women’s health.

Throughout his career, Adam has excelled as a project leader, advancing numerous programs from discovery to clinical evaluation. Notably, he is the lead inventor of P2X3R antagonists Eliapixant and Filopixant, which achieved Phase 2a Proof-of-Concept (PoC) in Persistent Chronic Cough (PCC), as well as the Bradykinin B1R antagonist Fulimetibant, which progressed into Phase 2a trials for diabetic neuropathic pain (DNP).

Adam’s leadership was further recognized through his promotion to Vice President of Medicinal Chemistry at Evotec, where he took on scientific and strategic portfolio responsibilities. As Executive Vice President and Head of Global Molecular Discovery, Adam led a multi-disciplinary, multi-modality design and synthesis organization spanning the UK, France, Italy, and the US, driving innovation and collaboration across teams.

Passionate about science and communication, Adam has authored over 60 patents, publications, and external presentations. He is also a co-recipient of the Bayer Healthcare Drug Discovery Award for Collaborative Innovation in 2017.

Adam holds a B.Sc. Honours degree in Chemistry and a Ph.D. in Organometallic Chemistry from the University of Leicester, UK.

About Proxygen

Proxygen is a leader in the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. While advancing its internal programs towards clinical development, the company also maintains various strategic partnerships to co-create synergies along the drug development pipeline. With its headquarters and laboratory operations in Vienna, Austria, Proxygen employs talent both locally and remotely all over Europe.

Contacts